Background Different imaging methods have been used to detect hepatocellular carcinoma (HCC). As there are increasing literature data about the role of radiolabelled choline PET/CT in this setting, we aimed to perform an updated meta-analysis about the detection rate (DR) of this imaging method in HCC. Methods A comprehensive computer literature search of studies published through December 2018 in PubMed/MEDLINE, Embase and Cochrane library databases regarding the DR of radiolabelled choline PET or PET/CT in patients with HCC was carried out. Pooled DR were calculated on a per patient-and on a per lesion-based analysis. Subgroup analyses taking into account the radiopharmaceutical used were performed. Results Nine studies (283 HCC patients) were included in the pooled analysis. The pooled DR of radiolabelled choline PET or PET/CT on a per patient-and on a per lesion-based analysis was 83% [95% confidence interval (95% CI) 75-89%] and 79% (95% CI 72-86%), respectively. A significant heterogeneity among the studies was found on a per lesion-based analysis only. No significant publication bias was found. The subgroup analysis demonstrated a trend towards a higher DR when using 18 F-choline compared to 11 C-choline, without a statistically significant difference. Pooled DR of HCC using dual-tracer PET/ CT (radiolabelled choline and 18 F-FDG) on a per patient-and a per lesion-based analysis was 91% (95% CI 87-95%) and 89% (95% CI 80-95%), respectively, without significant heterogeneity. Conclusions Radiolabelled choline PET/CT demonstrated good ability in detecting HCC. The DR increased when dual-tracer PET/CT was performed. Large multicenter studies and cost-effectiveness analyses are warranted.
Introduction
Hepatocellular carcinoma (HCC) is a global health issue with increasing incidence and high mortality rate [1] . The prognosis of patients with HCC is related to the tumour stage at diagnosis with higher chances to offer a curative treatment when HCC is diagnosed earlier [2] . Depending on the tumour load and extent of underlying liver cirrhosis, aggressive surgical treatment may lead to curing it, whereas different locoregional or systemic tumour treatments are currently available for a non-curative approach [1] .
Non-invasive diagnosis of HCC is possible through imaging methods. In cirrhotic patients, the diagnosis can be obtained in tumours displaying typical features that include non-rim arterial phase increased enhancement followed by washout during the portal venous and/or delayed phases on computed tomography (CT) or magnetic resonance imaging (MRI). This pattern is very specific, but its sensitivity is not very high. The use of hepatobiliary MRI contrast agents increases confidence in the diagnosis of HCC but cannot be used as substitutes for liver biopsy [3] .
Fluorine-18-fluorodeoxyglucose ( 18 F-FDG) is the most used radiopharmaceutical for positron emission tomography (PET) in oncology worldwide. This glucose analogue allows to study the glucose metabolism which is often increased in many tumours. Whereas 18 F-FDG PET has only a limited role in the diagnosis of HCC, it provides valuable prognostic information about this tumour [4] [5] [6] .
Compared to 18 F-FDG PET or PET/CT, radiolabelled choline PET or PET/CT seems to show a better diagnostic performance in detecting HCC [6] [7] [8] . As a phospholipid analogue, radiolabelled choline is integrated into the newly synthesized membranes of proliferating cells and its uptake is increased by upregulation of choline kinase [7] [8] [9] [10] . The increase in phosphatidylcholine turnover in HCC is the rationale for using radiolabelled choline PET for detecting these tumours [6] [7] [8] .
Due to the increasing literature data on the role of radiolabelled choline PET/CT in patients with HCC, we aimed to perform an updated systematic review and meta-analysis on the detection rate (DR) of HCC using this imaging method.
Methods
This systematic review and meta-analysis paper was written according to the "Preferred Reporting Items for Systematic Reviews and Meta-Analyses of Diagnostic Test Accuracy studies" (PRISMA-DTA) statement which describes an evidence-based minimum set of items for reporting in systematic reviews and meta-analyses of diagnostic studies [11] [12] [13] .
Search strategy
Two authors (GS and GT) performed a comprehensive computer literature search of PubMed/MEDLINE, Embase and Cochrane library databases to find relevant retrospective or prospective published articles on the diagnostic performance of radiolabelled choline PET or PET/CT in detecting HCC in human patients. This search algorithm based on a combination of terms was used: (A) "choline" or "fluorocholine" or "F-choline" or "C-choline" or "FCH" or "CH" or "FECH" or "FMCH" and (B) "PET" or "positron emission tomography" and (C) "HCC" or "hepatocellular". The search was updated until December 31, 2018 . No language restriction was applied. To expand the search, references of the retrieved articles were also screened for additional studies.
Study selection
Studies or subsets of studies investigating the diagnostic performance of radiolabelled choline PET in detecting HCC in human patients were eligible for inclusion in the qualitative analysis (systematic review). The exclusion criteria were: (a) articles not within the field of interest of this review; (b) review articles, editorials or letters, comments, conference proceedings; (c) case reports and case series. For the quantitative analysis (meta-analysis), we also excluded articles with insufficient data to reassess the diagnostic performance and studies with possible patient overlap. In case of possible patient overlap, the most complete article was included in the meta-analysis.
Two researchers (GS and GT) independently reviewed the titles and abstracts of the retrieved articles, applying the inclusion and exclusion criteria mentioned above. Articles were rejected if they were clearly ineligible. The same two researchers then independently reviewed the full-text version of the remaining articles to assess their eligibility for inclusion. Disagreements were resolved in a consensus meeting among all co-authors.
Data extraction
For each potentially eligible study, information was collected concerning basic study (authors, year of publication, country of origin, study design), patient characteristics (type and number of patients performing PET, mean or median age, sex ratio), technical aspects (radiotracer used, hybrid imaging modality, mean injected activity, time interval between radiotracer injection and image acquisition, image analysis and other imaging modalities compared with radiolabelled choline PET), reference standard, diagnostic performance and percentage of change of management using radiolabelled choline PET or PET/CT in HCC.
Quality assessment
The overall quality of the studies included in the systematic review was critically appraised based on the revised "Quality Assessment of Diagnostic Accuracy Studies" tool (QUA-DAS-2) [14] . This tool comprises four domains: patient selection, index test, reference standard, and flow and timing. Each domain is assessed in terms of risk of bias, and the first three domains are also assessed in terms of concerns regarding applicability [14] .
Statistical analysis
The DR of radiolabelled choline PET was calculated on a per patient-and a per lesion-based analysis. The DR was defined as the ratio between the number of HCC patients/ lesions detected at radiolabelled choline PET and the overall HCC patients/lesions according to the reference standard.
Pooled data were obtained using a random-effects model and presented with 95% confidence intervals (95% CI). Subgroup analyses were planned in case of significant heterogeneity.
Heterogeneity has been estimated using the I-square index (I 2 ) which describes the percentage of variation across studies that is due to heterogeneity rather than chance [15] . Publication bias was assessed through the Egger's test [16] . Statistical analyses were performed using StatsDirect 3 software (Cambridge, UK).
Results

Literature search
The comprehensive computer literature search from PubMed/MEDLINE, Embase and Cochrane library database revealed 178 articles. After reviewing titles and abstracts, 164 articles were excluded: 146 because it was not in the field of interest of this systematic review, 4 case reports, 14 reviews, editorials or letters. Fourteen articles were selected and retrieved in full-text version [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] . We did not find additional studies screening the references of the selected articles. Therefore, 14 studies (596 patients) were eligible for the qualitative analysis (systematic review). After reviewing the full-text articles, five studies were excluded from the quantitative analysis (meta-analysis): three for insufficient data to reassess the diagnostic performance of radiolabelled choline PET or PET/CT [17, 18, 20] and two for possible patient data overlap [23, 26] ; finally, nine studies (283 HCC patients) were selected for inclusion in the quantitative analysis (meta-analysis) [19, 21, 22, 24, 25, [27] [28] [29] [30] (Fig. 1 ). The characteristics of the studies selected for the systematic review are presented in Tables 1, 2 and 3. Overall quality assessment of the studies is reported in Fig. 2 .
Qualitative analysis (systematic review)
Basic study and patient characteristics
Using the database search, 14 full-text articles on the diagnostic performance of radiolabelled choline PET in 596 patients with suspected or diagnosed HCC were selected (Table 1) .
These articles were published between 2006 and 2018. Several countries from Europe, North America and Asia were represented. Eleven studies (79%) were prospective, two (14%) were retrospective and in one article (7%), the study design was not declared. All except one were single centre studies (93%).
In 11 out of 14 studies, radiolabelled choline PET was performed in patients with diagnosed HCC (newly diagnosed/primary or previously treated/recurrent HCC), whereas in the remaining studies this imaging method was performed in patients with suspicion of HCC.
Information about patient age was reported in 11 out of 14 articles, in 4 as median (ranging from 61 to 64 years) and in 7 as mean (ranging from 54.2 to 71 years). About the sex ratio, the mean percentage of male patients was approximately 80%. Among all the included patients, 526 (88%) had HCC and the remaining patients (12%) had other tumour types. Regarding the histological differentiation degree of HCC, this information was reported in 8 studies (179 patients) with a heterogenous distribution between highly, moderately and poorly differentiated HCC (Table 1) .
Technical aspects
Heterogeneous technical aspects among the included studies were found ( Table 2 ). The radiotracer injected was 18 F-choline in nine studies (64%) and 11 C-choline in five studies (36%). Thirteen studies (93%) used hybrid PET/CT, whereas only one study used a PET-alone tomograph. PET/CT was performed using a low-dose CT acquisition in almost all studies, whereas a contrast-enhanced CT combined with PET imaging was used in one study only. The reported mean injected activity of radiolabelled choline ranged between 250 and 740 MBq (in absolute values) and between 2.2 and 6 MBq/kg. The time interval between radiotracer injection and image acquisition was highly variable in the included studies ranging from 5 to 40 min after injection, based on the different radiotracers and isotopes used (the half-life of 11 C is lower compared to that of analysis was performed using qualitative (visual) analysis in all studies and additional semi-quantitative analysis through the calculation of the maximal standardized uptake values (SUV max ) of the detected lesions in almost all studies. Beyond the SUV max of the lesion, another semi-quantitative measure used was the tumour to background SUV max ratio, usually using the adjacent liver as background region ( Table 2 ). The use of SUV max ratio is especially useful with underlying parenchymal disease such as the cirrhotic liver, which affects the radiopharmaceutical uptake.
In three articles, radiolabelled choline PET/CT was the only imaging modality evaluated, whereas in the other studies, its diagnostic performance was compared with other imaging tests (including MRI, CT and 18 F-FDG PET/CT). Excluded from the meta-analysis for possible data overlap 
Main findings
Diagnostic accuracy data of radiolabelled choline PET/CT in patients with HCC from each study are listed in Table 3 . Overall, radiolabelled choline PET or PET/CT has demonstrated a good diagnostic performance in detecting HCC in almost all studies included in the systematic reviews, both on a per patient-and on a per lesion-based analysis [19, [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] . Despite a physiological uptake of radiolabelled choline in the liver, a significant higher uptake of radiolabelled choline in HCC nodules compared to normal liver was demonstrated both at visual and semi-quantitative analysis in most of the articles [18-24, 27, 29, 30] . A broad range of radiolabelled choline uptake in HCC lesions was observed, and lower liver parenchymal uptake of radiolabelled choline was noted in cirrhotic patients as compared to non-cirrhotic patients [23] . A trend towards a higher radiolabelled choline uptake was observed in well-differentiated HCC as compared to poorly differentiated tumours [18, 22, 29, 30] .
The most common causes of false negative HCC lesions at radiolabelled choline PET/CT were small, necrotic or nonwell-differentiated HCC lesions [19, [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] ; conversely, some false positive findings at radiolabelled choline PET/ CT were sometimes described in some benign lesions (i.e., benign hepatic or extrahepatic lesions, including benign tumours and inflammatory lesions) or other malignant tumours beyond HCC [24, 28] .
Beyond the detection of primary HCC lesions, several articles demonstrated that radiolabelled choline PET/CT may also be able to detect extrahepatic HCC lesions [17, 23-25, 28, 30] . As reported by some studies, radiolabelled choline PET/CT can detect additional lesions compared to conventional imaging techniques in patients with HCC, in particular extrahepatic lesions, leading to a change of management in a significant percentage of patients [17, 24, 25] . In particular, Lopci et al. showed a significant higher accuracy of radiolabelled choline PET in detecting extrahepatic lesions compared to conventional imaging (99% versus 32%, respectively) [24] .
No significant difference in DR between radiolabelled choline PET/CT performed for HCC staging versus restaging was observed [28] . Radiolabelled choline PET/CT was found positive even in those HCC patients with normal α-fetoprotein (AFP) serum levels [25, 28] .
A substantial reproducibility and concordance between masked readers of radiolabelled choline PET/CT in patients with suspicious HCC has been reported [28] .
In some studies, dual-tracer PET or PET/CT (using both radiolabelled choline and 18 F-FDG) in suspicious or known HCC patients was performed [17, 18, 21, 22, [26] [27] [28] [29] [30] . Overall, a superior DR of HCC lesions using radiolabelled choline PET/CT compared to 18 F-FDG PET/CT was found [21, 22, [26] [27] [28] [29] [30] . Of note, radiolabelled choline PET/CT tended to be more sensitive than 18 F-FDG PET/CT for well-differentiated HCC, whereas 18 F-FDG PET/CT tended to be more sensitive than radiolabelled choline PET/CT for poorly differentiated HCC [21, 22, [27] [28] [29] [30] . Overall, using dual-tracer PET or PET/CT, an increased detection of HCC was demonstrated compared to both radiolabelled choline or 18 F-FDG PET or PET/CT alone [17, 21, 22, [27] [28] [29] .
From a prognostic point of view, patients with HCC negative at 18 F-FDG and positive at radiolabelled choline PET/ CT showed a significantly lower rate of early recurrence and early death than all other HCC patients [21] .
When used for HCC staging, dual-tracer PET/CT enabled a change in treatment in 14% of patients; dual-tracer PET/CT was also found useful in specific situations as unexplained rise in AFP, doubtful lesions or pre-transplant evaluation of patients without active HCC [17] .
Quantitative analysis (meta-analysis)
Nine studies including 340 patients were selected for the meta-analysis on the diagnostic performance of radiolabelled choline PET or PET/CT in patients with HCC [19, 21, 22, 24, 25, [27] [28] [29] [30] . Of these nine studies, seven were available for the patient-based pooled analysis [19, 21, 22, [19, 21, 22, 24, 25, 28, 29] . Histological findings, non-invasive criteria, multidisciplinary workflow or follow-up were used as reference standard. For each study, these metrics about diagnostic accuracy were obtained on a per patient-based and on a per lesion-based analysis: DR, sensitivity and specificity (Table 3) . Due to the low number of articles with true negative and false positive findings, we have calculated the pooled DR as summary measure of diagnostic performance of radiolabelled choline PET or PET/ CT in HCC.
The DR of HCC using radiolabelled choline PET or PET/ CT on a per patient-based analysis ranged from 71 to 100% with a pooled estimate of 83% (95% CI 76-89%) (Fig. 3) . The heterogeneity among the included studies was moderate (I 2 = 34%). A publication bias was not detected by Egger's test (p = 0.21).
The DR of HCC using radiolabelled choline PET or PET/ CT on a per lesion-based analysis ranged from 63 to 91% with a pooled estimate of 79% (95% CI 72-86%) (Fig. 4) . The heterogeneity among the included studies was significant (I 2 = 58%). A publication bias was not detected by Egger's test (p = 0.25).
A subgroup analysis taking into account the radiopharmaceutical used ( 18 F-choline or 11 C-choline) was performed. Pooled DR of HCC using 18 F-choline PET or PET/CT on a per patient-and a per lesion-based analysis was 89% (95% CI 78-96%) and 86% (95% CI 81-91%), respectively. Pooled DR of HCC using 11 C-choline PET or PET/CT on a per patient-and a per lesion-based analysis was 78% (95% CI 70-86%) and 74% (95% CI 67-80%), respectively, without significant heterogeneity.
Lastly, the pooled DR of HCC using dual-tracer PET or PET/CT (radiolabelled choline and 18 F-FDG) on a per patient-and a per lesion-based analysis was 91% (95% CI 87-95%) and 89% (95% CI 80-95%), respectively, without significant heterogeneity and publication bias.
Discussion
A previous systematic review and meta-analysis evaluating the diagnostic performance of radiolabelled choline PET or PET/CT in patients with HCC was published in 2014 [8] . Since several articles on this topic were published in the last years, we aimed to perform an updated systematic Several studies have used radiolabelled choline PET or PET/CT for detecting HCC reporting different values of diagnostic performance [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] . However, most of these studies have limited power, due to the relatively small numbers of patients enrolled and assessed. To derive more robust estimates on the diagnostic performance of radiolabelled choline PET in this setting, we pooled the published studies.
Findings of our systematic review and meta-analysis indicate that radiolabelled choline PET or PET/CT show a good DR of both intrahepatic and extrahepatic HCC lesions with a pooled DR of 83% and 79% on a per patient-and a per lesion-based analysis, respectively (Figs. 3, 4 ). In case HCC shows no extrahepatic spread of disease, locoregional treatment is possible. However, extrahepatic metastases are not uncommon, and treatment of these patients is restricted to palliative systemic treatment with poor prognosis [1] . Therefore, accurate staging and restaging of HCC is crucial and radiolabelled choline PET/CT could be helpful for this purpose. The additional value of radiolabelled choline PET/CT lies in accurate whole-body assessment with regard to extent of disease, which has direct implications for staging and treatment decisions [17, 24, 25, 31] . It is well known that MRI is the most sensitive imaging modality for HCC intrahepatic lesions [3] ; therefore, the additional value of radiolabelled choline PET/CT does not lie in detection of HCC intrahepatic lesions, but in detection of HCC extrahepatic lesions to evaluate metastatic disease. In fact, additional extrahepatic HCC lesions can be found on radiolabelled choline PET/CT compared to conventional morphological imaging with treatment implications in a significant percentage of patients [17, 24, 25, 31] , suggesting the need to incorporate radiolabelled choline PET/CT into the diagnostic work up of HCC.
In our subgroup analysis, we found a trend towards a higher DR with 18 F-choline compared to 11 C-choline without a statistically significant difference. Imaging characteristics of 18 F-choline and 11 C-choline PET have been compared using the animal models of HCC with similar results among the two radiopharmaceuticals [32] . However, due to the relatively short half-life of 11 C compared to 18 F (20 min versus 110 min), the use of 11 C-choline is limited to centres with an on-site cyclotron and image acquisition has to be performed earlier after injection [7] .
Head-to-head comparison studies showed that the DR of HCC is higher using radiolabelled choline PET/CT compared to 18 F-FDG PET/CT [21, 22, 26, [28] [29] [30] . However, Fig. 4 Plots of individual studies and pooled DR of HCC using radiolabelled choline PET or PET/CT on a per lesion-based analysis, including 95% confidence intervals (95% CI). The size of the squares indicates the weight of each study the combination of the two imaging techniques increases the DR of HCC compared to each modality taken separately as even demonstrated by our subgroup analysis (pooled DR of dual-tracer PET or PET/CT was 91% and 89% on a per patient-and a per lesion-based analysis, respectively). In fact, in some cases, only one modality is able to identify new lesions. Different grades of HCC differentiation might explain this discrepancy, as radiolabelled choline usually has a propensity for accumulation in well-differentiated HCC, while less differentiated HCC are often more 18 F-FDG avid. Intuitively, it could be speculated that, in case of well-differentiated HCC, malignant hepatocytes incorporate more radiolabelled choline than the normal liver tissue, in relation with membrane proliferation and increased lipid metabolism; while losing their differentiation, malignant hepatocytes would also lose their usual metabolic pathways, become less radiolabelled choline avid and start consuming more glucose, which would explain the higher 18 F-FDG uptake [17, 21, 22, [26] [27] [28] [29] , Overall, the use of dual-tracer PET/CT could have an additional diagnostic value in patients with HCC, providing correct information on disease extent. Furthermore, dual-tracer PET/CT could have an additional prognostic value, as 18 F-FDG avidity appears to be more frequent in HCCs with a poor prognosis than in those with a good prognosis, whereas the inverse is true for radiolabelled choline avidity [21, 29] . Therefore, dual-tracer PET/ CT could be useful for the management of HCC patients. In HCC patients with normal AFP serum levels, which is most frequently well differentiated, radiolabelled choline PET/CT seems interesting because its DR was independent of AFP levels, contrary to the DR of 18 F-FDG PET/CT [28] . Heterogeneity among studies may be a source of bias in a meta-analysis. This heterogeneity is likely related to the baseline differences among the included patients in the selected articles (Table 1) , different methodological aspects between different studies (Table 2) , and different study quality. We detected a significant heterogeneity among the selected studies on a per lesion-based analysis only, but we have explored this heterogeneity performing different subgroup analyses.
The absence of histopathological analysis for all the HCC patients in the studies included in our analysis may be a potential source of bias, but clearly it is not ethical or technically feasible to have the histology of all detected lesions.
Publication bias may be a concern in a meta-analysis, as studies reporting positive findings are more likely to be published than those reporting negative results. To this regard, we did not find a significant publication bias in our meta-analysis.
It should be underlined that the diagnostic accuracy of a test is not a measure of clinical effectiveness; furthermore, improved diagnostic accuracy is not always associated with improved patient outcomes. Overall, our systematic review and meta-analysis demonstrated that radiolabelled choline PET or PET/CT has good ability in detecting HCC. Nevertheless, large prospective multicentric studies and in particular cost-effectiveness analyses investigating the inclusion of radiolabelled choline PET/CT in the diagnostic work up of patients with HCC are needed to strengthen the usefulness of this technique in this setting. These cost-effectiveness analyses should take into account several parameters beyond the diagnostic performance, including availability, radiation exposure and costs of different imaging modalities.
Obviously, radiolabelled choline PET/CT is not available in every medical centre and is a costly imaging modality. However, accurate HCC staging or restaging using radiolabelled choline PET/CT could prevent unnecessary interventions, including expensive surgery or locoregional treatment, potentially reducing the overall costs related to the management of patients with HCC.
The possibility of using radiolabelled choline PET to assess hepatocyte reserve in HCC patients may lead to expanded roles for this imaging method in risk stratification, pre-surgical planning, transplant candidate selection, and the monitoring of hepatotoxicity in systemically treated patients [23] .
Another promising investigative tool in HCC is combined PET/MRI that is now becoming available [33] . The advantages of PET/MRI compared to PET/CT are less radiation exposure and higher soft-tissue contrast [33] . Unfortunately, no studies currently exist that compare the diagnostic accuracy of radiolabelled choline PET/MRI and PET/ CT in detecting HCC, but this could be an object of future research.
Conclusions
Based on current literature data, radiolabelled choline PET/ CT demonstrated good ability in detecting HCC. The DR increases when dual-tracer PET/CT is performed. Larger multicenter prospective studies and cost-effectiveness analyses are needed to strengthen the role of radiolabelled choline PET/CT in this setting.
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